Joseph R Testa

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7803965/publications.pdf

Version: 2024-02-01

161 papers	13,657 citations	25034 57 h-index	22832 112 g-index
169 all docs	169 docs citations	169 times ranked	16301 citing authors

#	Article	IF	Citations
1	Inactivation of p21-Activated Kinase 2 (Pak2) Inhibits the Development of Nf2-Deficient Tumors by Restricting Downstream Hedgehog and Wnt Signaling. Molecular Cancer Research, 2022, 20, 699-711.	3.4	6
2	Asbestos and Other Hazardous Fibrous Minerals: Potential Exposure Pathways and Associated Health Risks. International Journal of Environmental Research and Public Health, 2022, 19, 4031.	2.6	16
3	Mesothelioma Mouse Models with Mixed Genomic States of Chromosome and Microsatellite Instability. Cancers, 2022, 14, 3108.	3.7	4
4	Somatic Epigenetic Silencing of RIPK3 Inactivates Necroptosis and Contributes to Chemoresistance in Malignant Mesothelioma. Clinical Cancer Research, 2021, 27, 1200-1213.	7.0	26
5	Kinetic Characterization of ASXL1/2-Mediated Allosteric Regulation of the BAP1 Deubiquitinase. Molecular Cancer Research, 2021, 19, 1099-1112.	3.4	1
6	NovelLRRK2mutations and other rare, non-BAP1-related candidate tumor predisposition gene variants in high-risk cancer families with mesothelioma and other tumors. Human Molecular Genetics, 2021, 30, 1750-1761.	2.9	7
7	DLX Genes: Roles in Development and Cancer. Cancers, 2021, 13, 3005.	3.7	27
8	Application of Chromosome Microarray Analysis for the Differential Diagnosis of Low-grade Renal Cell Carcinoma With Clear Cell and Papillary Features. Applied Immunohistochemistry and Molecular Morphology, 2020, 28, 123-129.	1.2	4
9	Monosomy of Chromosome 9 Is Associated With Higher Grade, Advanced Stage, and Adverse Outcome in Clear-cell Renal Cell Carcinoma. Clinical Genitourinary Cancer, 2020, 18, 56-61.	1.9	4
10	Hypomorphic mTOR Downregulates CDK6 and Delays Thymic Pre-T LBL Tumorigenesis. Molecular Cancer Therapeutics, 2020, 19, 2221-2232.	4.1	7
11	Wnt signaling mediates oncogenic synergy between Akt and Dlx5 in T-cell lymphomagenesis by enhancing cholesterol synthesis. Scientific Reports, 2020, 10, 15837.	3.3	6
12	BRCA1 Mutational Complementation Induces Synthetic Viability. Molecular Cell, 2020, 78, 951-959.e6.	9.7	41
13	Overall tumor genomic instability: an important predictor of recurrence-free survival in patients with localized clear cell renal cell carcinoma. Cancer Biology and Therapy, 2020, 21, 424-431.	3.4	8
14	Challenging Global Waste Management â€“ Bioremediation to Detoxify Asbestos. Frontiers in Environmental Science, 2020, 8, .	3.3	17
15	Preclinical Models of Malignant Mesothelioma. Frontiers in Oncology, 2020, 10, 101.	2.8	19
16	RPL22L1 induction in colorectal cancer is associated with poor prognosis and 5-FU resistance. PLoS ONE, 2019, 14, e0222392.	2.5	19
17	Thymine DNA glycosylase as a novel target for melanoma. Oncogene, 2019, 38, 3710-3728.	5.9	28
18	Inactivation of Bap1 Cooperates with Losses of Nf2 and Cdkn2a to Drive the Development of Pleural Malignant Mesothelioma in Conditional Mouse Models. Cancer Research, 2019, 79, 4113-4123.	0.9	42

#	Article	IF	Citations
19	Detecting MYB and MYBL1 fusion genes in tracheobronchial adenoid cystic carcinoma by targeted RNA-sequencing. Modern Pathology, 2019, 32, 1416-1420.	5.5	26
20	PBRM1 acts as a p53 lysine-acetylation reader to suppress renal tumor growth. Nature Communications, 2019, 10, 5800.	12.8	47
21	Clinical application of RNA sequencing in sarcoma diagnosis. Medicine (United States), 2019, 98, e16031.	1.0	24
22	NEAT1-TFE3 and KAT6A-TFE3 renal cell carcinomas, new members of MiT family translocation renal cell carcinoma. Modern Pathology, 2019, 32, 710-716.	5.5	54
23	The correlation between gain of chromosome 8q and survival in patients with clear and papillary renal cell carcinoma. Therapeutic Advances in Urology, 2018, 10, 3-10.	2.0	3
24	Familial and Somatic BAP1 Mutations Inactivate ASXL1/2-Mediated Allosteric Regulation of BAP1 Deubiquitinase by Targeting Multiple Independent Domains. Cancer Research, 2018, 78, 1200-1213.	0.9	24
25	Malignant Mesothelioma. Atlas of Genetics and Cytogenetics in Oncology and Haematology, 2018, , .	0.1	1
26	Comprehensive Study of the Clinical Phenotype of GermlineBAP1Variant-Carrying Families Worldwide. Journal of the National Cancer Institute, 2018, 110, 1328-1341.	6.3	164
27	BRCA1 Mutation-Specific Responses to 53BP1 Loss-Induced Homologous Recombination and PARP Inhibitor Resistance. Cell Reports, 2018, 24, 3513-3527.e7.	6.4	61
28	Inactivation of Tp53 and Pten drives rapid development of pleural and peritoneal malignant mesotheliomas. Journal of Cellular Physiology, 2018, 233, 8952-8961.	4.1	20
29	Multiple tumor suppressors regulate a HIF-dependent negative feedback loop via ISGF3 in human clear cell renal cancer. ELife, 2018, 7, .	6.0	25
30	Malignant Mesothelioma: An Asbestos Legacy. Current Cancer Research, 2017, , 1-9.	0.2	1
31	BAP1, a tumor suppressor gene driving malignant mesothelioma. Translational Lung Cancer Research, 2017, 6, 270-278.	2.8	54
32	Germline and Somatic Mutations in Human Mesothelioma and Lessons from Asbestos-Exposed Genetically Engineered Mouse Models. Current Cancer Research, 2017, , 175-195.	0.2	3
33	Haploinsufficiency in tumor predisposition syndromes: altered genomic transcription in morphologically normal cells heterozygous for VHL or TSC mutation. Oncotarget, 2017, 8, 17628-17642.	1.8	11
34	The homeoprotein Dlx5 drives murine T-cell lymphomagenesis by directly transactivating Notch and upregulating Akt signaling. Oncotarget, 2017, 8, 14941-14956.	1.8	9
35	Intratumoral heterogeneity analysis reveals hidden associations between protein expression losses and patient survival in clear cell renal cell carcinoma. Oncotarget, 2017, 8, 37423-37434.	1.8	16
36	Targeting MYC sensitizes malignant mesothelioma cells to PAK blockage-induced cytotoxicity. American Journal of Cancer Research, 2017, 7, 1724-1737.	1.4	8

#	Article	IF	Citations
37	Immunohistochemistry Successfully Uncovers Intratumoral Heterogeneity and Widespread Co-Losses of Chromatin Regulators in Clear Cell Renal Cell Carcinoma. PLoS ONE, 2016, 11, e0164554.	2.5	19
38	Ribosomal Protein Rpl22 Controls the Dissemination of T-cell Lymphoma. Cancer Research, 2016, 76, 3387-3396.	0.9	24
39	Genomic Copy Number Alterations in Renal Cell Carcinoma with Sarcomatoid Features. Journal of Urology, 2016, 195, 852-858.	0.4	22
40	Genomic imbalances in peripheral blood confirm the diagnosis of myelodysplastic syndrome in a patient presenting with non-immune hemolytic anemia. Leukemia Research Reports, 2016, 5, 23-26.	0.4	5
41	Appl1andAppl2are Expendable for Mouse Development But Are Essential for HGF-Induced Akt Activation and Migration in Mouse Embryonic Fibroblasts. Journal of Cellular Physiology, 2016, 231, 1142-1150.	4.1	13
42	Germline BAP1 Mutational Landscape of Asbestos-Exposed Malignant Mesothelioma Patients with Family History of Cancer. Cancer Research, 2016, 76, 206-215.	0.9	93
43	Flaxseed lignans enriched in secoisolariciresinol diglucoside prevent acute asbestos-induced peritoneal inflammation in mice. Carcinogenesis, 2016, 37, 177-187.	2.8	44
44	Bap1 Is a Bona Fide Tumor Suppressor: Genetic Evidence from Mouse Models Carrying Heterozygous Germline Bap1 Mutations. Cancer Research, 2016, 76, 2836-2844.	0.9	95
45	Genome-wide analysis of abdominal and pleural malignant mesothelioma with DNA arrays reveals both common and distinct regions of copy number alteration. Cancer Biology and Therapy, 2016, 17, 328-335.	3.4	47
46	Inflammation-Related IL1Î²/IL1R Signaling Promotes the Development of Asbestos-Induced Malignant Mesothelioma. Cancer Prevention Research, 2016, 9, 406-414.	1.5	68
47	SWOG S0722: Phase II Study of mTOR Inhibitor Everolimus (RAD001) in Advanced Malignant Pleural Mesothelioma (MPM). Journal of Thoracic Oncology, 2015, 10, 387-391.	1.1	67
48	Inhibition of mesothelioma cancer stemâ€like cells with adenovirusâ€mediated <scp>NK</scp>4 gene therapy. International Journal of Cancer, 2015, 137, 481-490.	5.1	13
49	Disregulated expression of the transcription factor ThPOK during T-cell development leads to high incidence of T-cell lymphomas. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 7773-7778.	7.1	18
50	Preclinical Efficacy for AKT Targeting in Clear Cell Carcinoma of the Ovary. Molecular Cancer Research, 2015, 13, 795-806.	3.4	25
51	Constitutively Active Akt1 Cooperates with KRasG12D to Accelerate In Vivo Pancreatic Tumor Onset and Progression. Neoplasia, 2015, 17, 175-182.	5.3	26
52	Co-targeting of Akt and Myc inhibits viability of lymphoma cells from Lck-Dlx5 mice. Cancer Biology and Therapy, 2015, 16, 580-588.	3.4	16
53	Mesothelioma patient derived tumor xenografts with defined BAP1 mutations that mimic the molecular characteristics of human malignant mesothelioma. BMC Cancer, 2015, 15, 376.	2.6	22
54	The roles of chromatin-remodelers and epigenetic modifiers in kidney cancer. Cancer Genetics, 2015, 208, 206-214.	0.4	48

#	Article	IF	Citations
55	Germline BAP1 mutation in a family with high incidence of multiple primary cancers and a potential geneâ€“environment interaction. Cancer Letters, 2015, 369, 261-265.	7.2	42
56	An asbestos-exposed family with multiple cases of pleural malignant mesothelioma without inheritance of a predisposing BAP1 mutation. Cancer Genetics, 2015, 208, 502-507.	0.4	13
57	Merlin Deficiency Predicts FAK Inhibitor Sensitivity: A Synthetic Lethal Relationship. Science Translational Medicine, 2014, 6, 237ra68.	12.4	203
58	Germline Mutation of Bap1 Accelerates Development of Asbestos-Induced Malignant Mesothelioma. Cancer Research, 2014, 74, 4388-4397.	0.9	129
59	Molecular Cytogenetic Analysis of the Scleractinian CoralAcropora solitaryensisVeron & Wallace 1984. Zoological Science, 2014, 31, 89-94.	0.7	12
60	Copy neutral loss of heterozygosity in 20q in chronic lymphocytic leukemia/small lymphocytic lymphoma. Cancer Genetics, 2014, 207, 98-102.	0.4	11
61	Tumor Suppressor Alterations Cooperate to Drive Aggressive Mesotheliomas with Enriched Cancer Stem Cells via a p53â€“miR-34aâ€“c-Met Axis. Cancer Research, 2014, 74, 1261-1271.	0.9	55
62	Further evidence for germline BAP1 mutations predisposing to melanoma and malignant mesothelioma. Cancer Genetics, 2013, 206, 206-210.	0.4	81
63	BAP1 and cancer. Nature Reviews Cancer, 2013, 13, 153-159.	28.4	522
64	NF-ÎºB Inhibition by Bortezomib Permits IFN-Î³â€“Activated RIP1 Kinaseâ€“Dependent Necrosis in Renal Cell Carcinoma. Molecular Cancer Therapeutics, 2013, 12, 1568-1578.	4.1	17
65	Potential Role of mTORC2 as a Therapeutic Target in Clear Cell Carcinoma of the Ovary. Molecular Cancer Therapeutics, 2013, 12, 1367-1377.	4.1	41
66	Cancer stemâ€like cell properties are regulated by <scp>EGFR</scp>/<scp>AKT</scp>/Î²â€“catenin signaling and preferentially inhibited by gefitinib in nasopharyngeal carcinoma. FEBS Journal, 2013, 280, 2027-2041.	4.7	81
67	Connecting Molecular Pathways to Hereditary Cancer Risk Syndromes. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2013, , 81-90.	3.8	14
68	Connecting Molecular Pathways to Hereditary Cancer Risk Syndromes. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2013, 33, 81-90.	3.8	19
69	Diverse Mechanisms of AKT Pathway Activation in Human Malignancy. Current Cancer Drug Targets, 2013, 13, 234-244.	1.6	156
70	Increasing the therapeutic index of 5-fluorouracil and 6-thioguanine by targeting loss of MTAP in tumor cells. Cancer Biology and Therapy, 2012, 13, 1082-1090.	3.4	25
71	Identification of Akt Interaction Protein PHF20/TZP That Transcriptionally Regulates p53. Journal of Biological Chemistry, 2012, 287, 11151-11163.	3.4	27
72	Inactivation of ribosomal protein L22 promotes transformation by induction of the stemness factor, Lin28B. Blood, 2012, 120, 3764-3773.	1.4	132

#	Article	IF	Citations
73	CD45-deficient severe combined immunodeficiency caused by uniparental disomy. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 10456-10461.	7.1	39
74	Chromothripsis in a case of TP53-deficient chronic lymphocytic leukemia. Leukemia Research Reports, 2012, 1, 4-6.	0.4	12
75	Group I p21-Activated Kinases (PAKs) Promote Tumor Cell Proliferation and Survival through the AKT1 and Rafâ€“MAPK Pathways. Molecular Cancer Research, 2012, 10, 1178-1188.	3.4	42
76	Frequent genetic abnormalities of the PI3K/AKT pathway in primary ovarian cancer predict patient outcome. Genes Chromosomes and Cancer, 2011, 50, 606-618.	2.8	90
77	ERK2 is essential for the growth of human epithelioid malignant mesotheliomas. International Journal of Cancer, 2011, 129, 1075-1086.	5.1	38
78	An Extracellular Signalâ€“Regulated Kinase 2 Survival Pathway Mediates Resistance of Human Mesothelioma Cells to Asbestos-Induced Injury. American Journal of Respiratory Cell and Molecular Biology, 2011, 45, 906-914.	2.9	14
79	Germline BAP1 mutations predispose to malignant mesothelioma. Nature Genetics, 2011, 43, 1022-1025.	21.4	924
80	Factors that Impact Susceptibility to Fiber-Induced Health Effects. Journal of Toxicology and Environmental Health - Part B: Critical Reviews, 2011, 14, 246-266.	6.5	19
81	Pten mediates Myc oncogene dependence in a conditional zebrafish model of T cell acute lymphoblastic leukemia. Journal of Experimental Medicine, 2011, 208, 1595-1603.	8.5	104
82	Losses of Both Products of the Cdkn2a/Arf Locus Contribute to Asbestos-Induced Mesothelioma Development and Cooperate to Accelerate Tumorigenesis. PLoS ONE, 2011, 6, e18828.	2.5	59
83	Onconase responsive genes in human mesothelioma cells: implications for an RNA damaging therapeutic agent. BMC Cancer, 2010, 10, 34.	2.6	29
84	Genetic Dissection of the Oncogenic mTOR Pathway Reveals Druggable Addiction to Translational Control via 4EBP-eIF4E. Cancer Cell, 2010, 17, 249-261.	16.8	420
85	T-Lymphoblastic Lymphoma Cells Express High Levels of BCL2, S1P1, and ICAM1, Leading to a Blockade of Tumor Cell Intravasation. Cancer Cell, 2010, 18, 353-366.	16.8	141
86	Combined classical cytogenetics and microarrayâ€based genomic copy number analysis reveal frequent 3;5 rearrangements in clear cell renal cell carcinoma. Genes Chromosomes and Cancer, 2010, 49, 610-619.	2.8	22
87	The biology of ovarian cancer development. Cancer, 2010, 71, 530-536.	4.1	91
88	Appl1 is dispensable for Akt signaling in vivo and mouse Tâ€cell development. Genesis, 2010, 48, 531-539.	1.6	15
89	Inflammation precedes the development of human malignant mesotheliomas in a SCID mouse xenograft model. Annals of the New York Academy of Sciences, 2010, 1203, 7-14.	3.8	74
90	Vascular Endothelial Growth Factor Is a Promising Therapeutic Target for the Treatment of Clear Cell Carcinoma of the Ovary. Molecular Cancer Therapeutics, 2010, 9, 2411-2422.	4.1	76

#	Article	IF	Citations
91	Appl1 Is Dispensable for Mouse Development, and Loss of Appl1 Has Growth Factor-selective Effects on Akt Signaling in Murine Embryonic Fibroblasts. Journal of Biological Chemistry, 2010, 285, 6377-6389.	3.4	49
92	Upregulation of DLX5 Promotes Ovarian Cancer Cell Proliferation by Enhancing IRS-2-AKT Signaling. Cancer Research, 2010, 70, 9197-9206.	0.9	49
93	A Phosphotyrosine Proteomic Screen Identifies Multiple Tyrosine Kinase Signaling Pathways Aberrantly Activated in Malignant Mesothelioma. Genes and Cancer, 2010, 1, 493-505.	1.9	48
94	Blocking of ERK1 and ERK2 sensitizes human mesothelioma cells to doxorubicin. Molecular Cancer, 2010, 9, 314.	19.2	64
95	GSK690693 Delays Tumor Onset and Progression in Genetically Defined Mouse Models Expressing Activated Akt. Clinical Cancer Research, 2010, 16, 486-496.	7.0	49
96	FAS-Associated Factor 1 (FAF1): Diverse functions and implications for oncogenesis. Cell Cycle, 2009, 8, 2528-2534.	2.6	80
97	Loss of GATA6 Leads to Nuclear Deformation and Aneuploidy in Ovarian Cancer. Molecular and Cellular Biology, 2009, 29, 4766-4777.	2.3	56
98	mTOR Is a Promising Therapeutic Target Both in Cisplatin-Sensitive and Cisplatin-Resistant Clear Cell Carcinoma of the Ovary. Clinical Cancer Research, 2009, 15, 5404-5413.	7.0	151
99	Activated TNF-Î±/NF-ÎºB signaling via down-regulation of Fas-associated factor 1 in asbestos-induced mesotheliomas from Arf knockout mice. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 3420-3425.	7.1	69
100	DLX5 (Distal-less Homeobox 5) Promotes Tumor Cell Proliferation by Transcriptionally Regulating MYC. Journal of Biological Chemistry, 2009, 284, 20593-20601.	3.4	41
101	Genomic events associated with progression of pleural malignant mesothelioma. International Journal of Cancer, 2009, 124, 589-599.	5.1	67
102	Recurrent chromosomal rearrangements implicate oncogenes contributing to Tâ€cell lymphomagenesis in Lckâ€MyrAkt2 transgenic mice. Genes Chromosomes and Cancer, 2009, 48, 786-794.	2.8	16
103	High density DNA array analysis reveals distinct genomic profiles in a subset of gastrointestinal stromal tumors. Genes Chromosomes and Cancer, 2009, 48, 886-896.	2.8	37
104	Activated cAMP Response Element Binding Protein Is Overexpressed in Human Mesotheliomas and Inhibits Apoptosis. American Journal of Pathology, 2009, 175, 2197-2206.	3.8	43
105	Mesothelioma Epidemiology, Carcinogenesis, and Pathogenesis. Current Treatment Options in Oncology, 2008, 9, 147-157.	3.0	207
106	A Novel Recurrent Chromosomal Inversion Implicates the Homeobox GeneDlx5in T-Cell Lymphomas from Lck-Akt2 Transgenic Mice. Cancer Research, 2008, 68, 1296-1302.	0.9	31
107	HGF Mediates Cell Proliferation of Human Mesothelioma Cells through a PI3K/MEK5/Fra-1 Pathway. American Journal of Respiratory Cell and Molecular Biology, 2008, 38, 209-217.	2.9	63
108	Insulin-like growth factor 1 receptor is a potential therapeutic target for gastrointestinal stromal tumors. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 8387-8392.	7.1	225

#	Article	IF	Citations
109	A Novel Mechanism of Late Gene Silencing Drives SV40 Transformation of Human Mesothelial Cells. Cancer Research, 2008, 68, 9488-9496.	0.9	27
110	Whole-Genome Profiling in Liposarcomas Reveals Genetic Alterations Common to Specific Telomere Maintenance Mechanisms. Cancer Research, 2007, 67, 9221-9228.	0.9	20
111	RAD001 (Everolimus) Delays Tumor Onset and Progression in a Transgenic Mouse Model of Ovarian Cancer. Cancer Research, 2007, 67, 2408-2413.	0.9	178
112	Phase II Study of Erlotinib in Patients With Malignant Pleural Mesothelioma: A Southwest Oncology Group Study. Journal of Clinical Oncology, 2007, 25, 2406-2413.	1.6	219
113	RAD001 Inhibits Human Ovarian Cancer Cell Proliferation, Enhances Cisplatin-Induced Apoptosis, and Prolongs Survival in an Ovarian Cancer Model. Clinical Cancer Research, 2007, 13, 4261-4270.	7.0	216
114	APPL1 Associates with TrkA and GIPC1 and Is Required for Nerve Growth Factor-Mediated Signal Transduction. Molecular and Cellular Biology, 2006, 26, 8928-8941.	2.3	137
115	TNF-Î± inhibits asbestos-induced cytotoxicity via a NF-Î²B-dependent pathway, a possible mechanism for asbestos-induced oncogenesis. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 10397-10402.	7.1	280
116	GIPC Is Recruited by APPL to Peripheral TrkA Endosomes and Regulates TrkA Trafficking and Signaling. Molecular and Cellular Biology, 2006, 26, 8942-8952.	2.3	124
117	Human and mouse mesotheliomas exhibit elevated AKT/PKB activity, which can be targeted pharmacologically to inhibit tumor cell growth. Oncogene, 2005, 24, 6080-6089.	5.9	153
118	Perturbations of the AKT signaling pathway in human cancer. Oncogene, 2005, 24, 7455-7464.	5.9	1,184
119	AKT signaling in normal and malignant cells. Oncogene, 2005, 24, 7391-7393.	5.9	252
120	A Mouse Model Recapitulating Molecular Features of Human Mesothelioma. Cancer Research, 2005, 65, 8090-8095.	0.9	152
121	The NF2 Tumor Suppressor Gene Product, Merlin, Inhibits Cell Proliferation and Cell Cycle Progression by Repressing Cyclin D1 Expression. Molecular and Cellular Biology, 2005, 25, 2384-2394.	2.3	155
122	Human Follicle-Stimulating Hormone (FSH) Receptor Interacts with the Adaptor Protein APPL1 in HEK 293 Cells: Potential Involvement of the PI3K Pathway in FSH Signaling1. Biology of Reproduction, 2004, 71, 629-636.	2.7	104
123	Altered gene expression in phenotypically normal renal cells from carriers of tumor suppressor gene mutations. Cancer Biology and Therapy, 2004, 3, 1313-1321.	3.4	24
124	Tumor suppressor genes and the two-hit model of recessive oncogenesis: Celebrating Alfred Knudson's 80th birthday. Genes Chromosomes and Cancer, 2003, 38, 286-287.	2.8	7
125	p21-activated Kinase Links Rac/Cdc42 Signaling to Merlin. Journal of Biological Chemistry, 2002, 277, 883-886.	3.4	236
126	Detection of SV40 DNA sequences in malignant mesothelioma specimens from the United States, but not from Turkey. Journal of Cellular Biochemistry, 2002, 84, 455-459.	2.6	39

#	Article	IF	Citations
127	Frequent activation of AKT2 kinase in human pancreatic carcinomas. Journal of Cellular Biochemistry, 2002, 87, 470-476.	2.6	131
128	Akt1 and Akt2 Differently Regulate Muscle Creatine Kinase and Myogenin Gene Transcription in Insulin-Induced Differentiation of C2C12 Myoblasts. Endocrinology, 2002, 143, 820-828.	2.8	20
129	Genetic-susceptibility factor and malignant mesothelioma in the Cappadocian region of Turkey. Lancet, The, 2001, 357, 444-445.	13.7	250
130	Genomic imbalances in human lung adenocarcinomas and squamous cell carcinomas. Genes Chromosomes and Cancer, 2001, 31, 282-287.	2.8	101
131	Absence of post-transcriptional RNA modifications ofBCL10 in human malignant mesothelioma and colorectal cancer. Genes Chromosomes and Cancer, 2001, 30, 96-98.	2.8	5
132	Human hepatocellular carcinoma is characterized by a highly consistent pattern of genomic imbalances, including frequent loss of 16q23.1-24.1. Genes Chromosomes and Cancer, 2001, 30, 245-253.	2.8	65
133	Loss of heterozygosity analysis defines a 3-cM region of 15q commonly deleted in human malignant mesothelioma. Oncogene, 2001, 20, 6245-6249.	5.9	20
134	Cyclin T2A Gene Maps on Human Chromosome 2q21. Journal of Histochemistry and Cytochemistry, 2001, 49, 693-697.	2.5	16
135	Loss of heterozygosity analysis of 13q and 14q in human malignant mesothelioma. Genes Chromosomes and Cancer, 2000, 28, 337-341.	2.8	27
136	Expression of GPC3, an X-linked recessive overgrowth gene, is silenced in malignant mesothelioma. Oncogene, 2000, 19, 410-416.	5.9	142
137	Loss of heterozygosity analysis of 13q and 14q in human malignant mesothelioma. , 2000, 28, 337.		1
138	Identification of a chromosome 3p14.3-21.1 gene, APPL, encoding an adaptor molecule that interacts with the oncoprotein-serine/threonine kinase AKT2. Oncogene, 1999, 18, 4891-4898.	5.9	190
139	Asbestos, chromosomal deletions, and tumor suppressor gene alterations in human malignant mesothelioma. Journal of Cellular Physiology, 1999, 180, 150-157.	4.1	139
140	Frequent mutations of NF2 and allelic loss from chromosome band 22q12 in malignant mesothelioma: Evidence for a two-hit mechanism ofNF2 inactivation. Genes Chromosomes and Cancer, 1999, 24, 238-242.	2.8	97
141	A new human synovial sarcoma cell line, HS-SY-3, with a truncated form of hybridSYT/SSX1 gene. , 1999, 82, 459-464.		23
142	Akt2 mRNA is highly expressed in embryonic brown fat and the AKT2 kinase is activated by insulin. Oncogene, 1998, 16, 2407-2411.	5.9	118
143	Translocation and activation of AKT2 in response to stimulation by insulin. Journal of Cellular Biochemistry, 1998, 70, 433-441.	2.6	28
144	Amplification and overexpression of theAKT2 oncogene in a subset of human pancreatic ductal adenocarcinomas. Molecular Carcinogenesis, 1998, 21, 81-86.	2.7	276

#	Article	IF	Citations
145	Amplification and overexpression of the AKT2 oncogene in a subset of human pancreatic ductal adenocarcinomas. Molecular Carcinogenesis, 1998, 21, 81-86.	2.7	2
146	Identification of a zinc-finger gene at 6q25: a chromosomal region implicated in development of many solid tumors. Oncogene, 1997, 14, 1973-1979.	5.9	92
147	Transforming activity and mitosis-related expression of the AKT2 oncogene: evidence suggesting a link between cell cycle regulation and oncogenesis. Oncogene, 1997, 14, 2793-2801.	5.9	139
148	Association of Krev-1/rap1a with Krit1, a novel ankyrin repeat-containing protein encoded by a gene mapping to 7q21-22. Oncogene, 1997, 15, 1043-1049.	5.9	213
149	Detection of DNA gains and losses in primary endometrial carcinomas by comparative genomic hybridization. , 1997, 18, 115-125.		64
150	Combined chromosome microdissection and comparative genomic hybridization detect multiple sites of amplified DNA in a human lung carcinoma cell line. Genes Chromosomes and Cancer, 1997, 20, 208-212.	2.8	30
151	Comparative genomic hybridization detects frequent overrepresentation of chromosomal material from 3q26, 8q24, and 20q13 in human ovarian carcinomas. Genes Chromosomes and Cancer, 1997, 20, 320-328.	2.8	169
152	Detection of low-fraction K-ras mutations in primary lung tumors using a sensitive method. , 1997, 74, 162-170.		17
153	Comparative genomic hybridization detects frequent overrepresentation of chromosomal material from 3q26, 8q24, and 20q13 in human ovarian carcinomas. Genes Chromosomes and Cancer, 1997, 20, 320-328.	2.8	2
154	Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas. International Journal of Cancer, 1995, 64, 280-285.	5.1	781
155	Deletion mapping of the short arm of chromosome 3 in human malignant mesothelioma. Genes Chromosomes and Cancer, 1994, 9, 76-80.	2.8	37
156	Cytogenetic analysis of 63 non-small cell lung carcinomas: Recurrent chromosome alterations amid frequent and widespread genomic upheaval. Genes Chromosomes and Cancer, 1994, 11, 178-194.	2.8	72
157	Cytogenetic abnormalities in non-small cell lung carcinoma: Similarity of findings in conventional and feeder cell layer cultures. Genes Chromosomes and Cancer, 1993, 6, 30-38.	2.8	6
158	Involvement of theRAFI locus, at band 3p25, in the 3p deletion of small-cell lung cancer. Genes Chromosomes and Cancer, 1991, 3, 283-293.	2.8	36
159	Chromosome alterations in 21 non-small cell lung carcinomas. Genes Chromosomes and Cancer, 1990, 2, 328-338.	2.8	64
160	Recurring loss involving chromosomes 1, 3, and 22 in malignant mesothelioma: Possible sites of tumor suppressor genes. Genes Chromosomes and Cancer, 1989, 1, 148-154.	2.8	91
161	SV40 infection induces telomerase activity in human mesothelial cells. , 0, .		1